The Chemours Company
NYSE:CCChemicals - Specialty
-$0.27 today
- Market cap
- $1.82B
- Beta
- 1.39
- P/E (TTM)
- -8.0
- EPS (TTM)
- -$2.73
- Dividend yield
- 1.61%
Volume 2.86M
Average 2.80M
CC Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
The Chemours CompanyNYSE: CC
Total Equity · Q2 FY2026 · quarter ended Jun 2026
Total equity turns negative
Q2 FY2026 total equity was -$48M, compared with $239M a year earlier. Over 3 fiscal years it compounded at -39.0% a year.
Context
- Total equity amounted to 0.7% of total assets at the end of Q2 FY2026, down 2.5 pp from a year earlier.
- Total equity increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total equity keeps falling in the next quarterly balance sheet after a -120.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 251M USD
- Year-over-year change
- -58.5%
- 4-year CAGR
- -30.6%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 251M | -58.5% |
| FY2024 | 2024-12-31 | 605M | -18.1% |
| FY2023 | 2023-12-31 | 739M | -33.2% |
| FY2022 | 2022-12-31 | 1.11B | +2.3% |
| FY2021 | 2021-12-31 | 1.08B | — |
Total Equity vs competitors
How CC compares with its peers on the latest reported figures
- CC's Jun 2026 total equity of -$48M is the lowest of the 19 companies compared; the peer median is $2.02B.
- Its year-over-year change of -120.1% is the lowest of 19, against a peer median of +3.4%.
- Total equity amounts to 0.7% of total assets for CC, versus a peer median of 46.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $40.62B | +1.6% | -1.3% | 46.0% | |
| Sep 2026 | $20.02B | +15.4% | +8.2% | 48.6% | |
| Jun 2026 | $14.01B | -3.0% | -7.2% | 55.7% | |
| Sep 2026 | $11.26B | +5.0% | -7.1% | 32.4% | |
| Sep 2026 | $9.17B | -7.8% | -3.9% | 47.5% | |
| Jun 2026 | $8.59B | +10.9% | +6.5% | 38.1% | |
| Sep 2026 | $2.89B | +8.2% | +4.6% | 49.3% | |
| Jun 2026 | $2.57B | +11.2% | +16.9% | 33.4% | |
| Aug 2026 | $2.17B | +10.7% | +7.5% | 39.9% | |
| Jun 2026 | $1.87B | -1.0% | -16.1% | 40.8% | |
| Jun 2026 | $1.73B | +3.0% | +18.2% | 43.6% | |
| Sep 2026 | $1.42B | +3.7% | +2.5% | 48.6% | |
| Jun 2026 | $1.26B | +8.9% | +6.1% | 53.1% | |
| Sep 2026 | $1.15B | +23.7% | +1.6% | 63.4% | |
| Jun 2026 | $1.02B | -13.3% | -0.2% | 31.5% | |
| Mar 2026 | $575.2M | -17.7% | -5.1% | 46.1% | |
| Mar 2026 | $379.5M | -18.6% | -5.8% | 19.7% | |
| Mar 2026 | $141.93M | -24.7% | -18.2% | 79.3% | |
| Jun 2026 | -$48M | -120.1% | -39.0% | 0.7% | |
| Peer median (excluding CC) | $2.02B | +3.4% | +0.7% | 46.1% | |
Competitors are the stored peer set for CC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 1.45B | 1.1B | 1.2B | 713M | 672M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 720M | 626M | 610M | 770M | 679M |
| Inventory | 1.1B | 1.4B | 1.35B | 1.47B | 1.57B |
| Other Current Assets | 0 | 82M | 705M | 71M | 81M |
| Total Current Assets | 3.35B | 3.21B | 3.84B | 3.03B | 3B |
| Property, Plant & Equipment (Net) | 3.38B | 3.41B | 3.48B | 3.44B | 3.35B |
| Goodwill | 102M | 102M | 102M | 46M | 46M |
| Intangible Assets | 6M | 13M | 3M | 3M | 2M |
| Long-term Investments | 169M | 175M | 158M | 152M | 160M |
| Tax Assets | 171M | 152M | 303M | 291M | 254M |
| Other Non-current Assets | 376M | 573M | 374M | 556M | 570M |
| Total Non-current Assets | 4.21B | 4.43B | 4.42B | 4.49B | 4.38B |
| Total Assets | 7.55B | 7.64B | 8.25B | 7.52B | 7.38B |
| Account Payables | 1.14B | 1.21B | 1.13B | 1.12B | 929M |
| Short-term Debt | 25M | 43M | 51M | 54M | 104M |
| Tax Payables | 64M | 42M | 28M | 44M | 0 |
| Deferred Revenue | 3M | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 440M | 325M | 1.13B | 554M | 547M |
| Total Current Liabilities | 1.86B | 1.89B | 2.49B | 1.8B | 1.69B |
| Long-term Debt | 3.72B | 3.59B | 3.94B | 4.02B | 4.26B |
| Deferred Tax Liabilities | 49M | 61M | 44M | 35M | 37M |
| Deferred Revenue (Non-current) | 2M | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 656M | 793M | 789M | 824M | 927M |
| Total Non-current Liabilities | 4.61B | 4.64B | 5.03B | 5.11B | 5.45B |
| Total Liabilities | 6.47B | 6.53B | 7.51B | 6.91B | 7.13B |
| Common Stock | 2M | 2M | 2M | 2M | 2M |
| Retained Earnings | 1.75B | 2.17B | 1.78B | 1.72B | 1.22B |
| Accumulated OCI | (364M) | (343M) | (274M) | (367M) | (244M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 1M | 0 | 2M | 1M | 1M |
| Total Equity | 1.08B | 1.11B | 739M | 605M | 251M |
| Total Debt | 3.99B | 3.88B | 4.3B | 4.36B | 4.59B |
| Net Debt | 2.54B | 2.78B | 3.1B | 3.64B | 3.91B |
The Chemours Company
NYSE:CC
Intrinsic Alpha fair value
Locked
Current Price
$12.09
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.